Literature DB >> 4577178

Resistance to arbovirus challenge in mice immediately after vaccination.

J Casals, S M Buckley, D W Barry.   

Abstract

Mice vaccinated with a single injection of formalin-inactivated suspensions of mouse brain tissue infected with arboviruses were markedly protected against a challenge injection administered hours later. The protection observed during the first 2 days after vaccination seemed to be nonspecific, in that it appeared not only with the homologous system but also between arboviruses of different antigenic groups; this phase may be associated with an interferon-like activity of the serum. Overlapping the nonspecific phase was one of specific protection, which seemed to be well-established in its own right by day 3 or 4 after vaccination. Serum neutralizing antibodies against the homologous viruses were detected as early as 24 h after vaccination and in almost all instances by day 3.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4577178      PMCID: PMC380907          DOI: 10.1128/am.25.5.755-762.1973

Source DB:  PubMed          Journal:  Appl Microbiol        ISSN: 0003-6919


  11 in total

1.  CROSS-PROTECTION IN ANIMALS INFECTED WITH GROUP A ARBOVIRUSES.

Authors:  H J HEARN; C T RAINEY
Journal:  J Immunol       Date:  1963-05       Impact factor: 5.422

2.  DEVELOPMENT OF INTERFERON IN RABBIT DERMIS AFTER INFECTION WITH HERPES SIMPLEX VIRUS.

Authors:  E E FORCE; R C STEWART; R F HAFF
Journal:  Virology       Date:  1965-02       Impact factor: 3.616

3.  A model in mice for the pathogenesis and treatment of rabies.

Authors:  G M Baer; W F Cleary
Journal:  J Infect Dis       Date:  1972-05       Impact factor: 5.226

4.  A protective mechanism induced by live group B arboviruses against heterologous group B arboviruses independent of serum neutralizing antibodies or interferon.

Authors:  W H Price; I S Thind; W O'Leary; A H el Dadah
Journal:  Am J Epidemiol       Date:  1967-07       Impact factor: 4.897

5.  Serological characterization of Eurasian Kemerovo group viruses. II. Cross plaque neutralization tests.

Authors:  H Libíková; S M Buckley
Journal:  Acta Virol       Date:  1971-01       Impact factor: 1.162

6.  Localized rabies infection in mice.

Authors:  T J Wiktor; H Koprowski; L B Rorke
Journal:  Proc Soc Exp Biol Med       Date:  1972-07

7.  Characterization of viruses isolated from bats.

Authors:  N Karabatsos
Journal:  Am J Trop Med Hyg       Date:  1969-09       Impact factor: 2.345

8.  Characterization of the Tacaribe group of arboviruses. I. Propagation and plaque assay of Tacaribe virus in a line of African green monkey kidney cells (Vero).

Authors:  B Simizu; J S Rhim; N H Wiebenga
Journal:  Proc Soc Exp Biol Med       Date:  1967-05

9.  THE FORMATION AND PROPERTIES OF POLIOVIRUS-NEUTRALIZING ANTIBODY. I. 19S AND 7S ANTIBODY FORMATION: DIFFERENCES IN KINETICS AND ANTIGEN DOSE REQUIREMENT FOR INDUCTION.

Authors:  S E SVEHAG; B MANDEL
Journal:  J Exp Med       Date:  1964-01-01       Impact factor: 14.307

10.  Factors modifying host resistance to viral infection. 3. Effect of whole body x-irradiation on experimental encephalomyocarditis virus infection in mice.

Authors:  B R Murphy; L A Glasgow
Journal:  J Exp Med       Date:  1968-05-01       Impact factor: 14.307

View more
  8 in total

1.  Response of irradiated mice to live-virus (TC-83) immunization.

Authors:  R O Spertzel; D E Hilmas; J R Brown; D W Mason
Journal:  Infect Immun       Date:  1975-03       Impact factor: 3.441

2.  An attenuated variant of Eastern encephalitis virus: biological properties and protection induced in mice.

Authors:  A Brown; J E Officer
Journal:  Arch Virol       Date:  1975       Impact factor: 2.574

3.  Production of defective interfering virus in the brains of mice by an avirulent, in contrast with a virulent, strain of Semliki forest virus.

Authors:  C G Woodward; H Smith
Journal:  Br J Exp Pathol       Date:  1975-08

4.  Mouse interferon in ascitic fluids.

Authors:  S M Buckley; J Casals
Journal:  Appl Microbiol       Date:  1974-08

5.  CNS pathogenesis following a dual viral infection with Semliki Forest (alphavirus) and Langat (flavivirus).

Authors:  S Amor; H E Webb
Journal:  Br J Exp Pathol       Date:  1988-04

6.  Acute infection with venezuelan equine encephalitis virus replicon particles catalyzes a systemic antiviral state and protects from lethal virus challenge.

Authors:  Jennifer L Konopka; Joseph M Thompson; Alan C Whitmore; Drue L Webb; Robert E Johnston
Journal:  J Virol       Date:  2009-09-30       Impact factor: 5.103

7.  Neutralizing antibodies protect mice against Venezuelan equine encephalitis virus aerosol challenge.

Authors:  Natasha M Kafai; Lauren E Williamson; Elad Binshtein; Soila Sukupolvi-Petty; Christina L Gardner; Jaclyn Liu; Samantha Mackin; Arthur S Kim; Nurgun Kose; Robert H Carnahan; Ana Jung; Lindsay Droit; Douglas S Reed; Scott A Handley; William B Klimstra; James E Crowe; Michael S Diamond
Journal:  J Exp Med       Date:  2022-03-17       Impact factor: 17.579

8.  Therapeutic monoclonal antibody treatment protects nonhuman primates from severe Venezuelan equine encephalitis virus disease after aerosol exposure.

Authors:  Crystal W Burke; Jeffery W Froude; Franco Rossi; Charles E White; Crystal L Moyer; Jane Ennis; M Louise Pitt; Stephen Streatfield; R Mark Jones; Konstantin Musiychuk; Jukka Kervinen; Larry Zeitlin; Vidadi Yusibov; Pamela J Glass
Journal:  PLoS Pathog       Date:  2019-12-02       Impact factor: 6.823

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.